IRVINE, Calif., Aug. 29, 2005 (PRIMEZONE) -- "Guidant Corporation's (NYSE:GDT) announcement that the company has received Phase II approval from the Food and Drug Administration (FDA) to expand enrollment in the U.S. portion of its SPIRIT III drug eluting stent clinical trial sparked interest in the market," stated SmallCap Sentinel analyst, D.R. Clark. "Company shares traded enormous volume the day of and following the FDA announcement. Clearly, this indicates great interest in stent related news and success stories."
The informational report "Innovations in Biotechnology" is available free of charge at www.SmallCapSentinel.com and will address various stent-related companies including Johnson and Johnson (NYSE:JNJ), MIV Therapeutics, Inc. (OTCBB:MIVT), Boston Scientific Corp. (NYSE:BSX) and the aforementioned.
MIV Therapeutics, Inc. is a developer of next-generation biocompatible stent coatings and drug delivery technologies for cardiovascular stents and for a broad range of implantable medical devices. The company recently announced that it had received a $4.14 million equity financing to accelerate research efforts.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/tcp/mivt/factsheet.html . Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics Corp. for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.